Lidocaine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lidocaine: From Local Anaesthesia to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Lidocaine is a well-established amide-type local anaesthetic; no original-indication text was recorded in this evidence pack, and Lidocaine currently holds no marketing registration in South Africa. The TxGNN model predicts possible efficacy for punctate epithelial keratoconjunctivitis, but this prediction is supported by 0 clinical trials and 0 publications — it rests on model similarity alone, and the available mechanistic reasoning points against therapeutic benefit.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack (Lidocaine is a known amide-type local anaesthetic / Class Ib antiarrhythmic) |
| Predicted New Indication | Punctate Epithelial Keratoconjunctivitis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Lidocaine is an amide-type local anaesthetic that blocks voltage-gated sodium channels, primarily used for local/regional anaesthesia and, in some settings, as a Class Ib antiarrhythmic. Its efficacy in these established uses is well proven.
No original-indication text was captured for this candidate, so the pharmacological relationship between Lidocaine’s established sodium-channel-blocking action and punctate epithelial keratoconjunctivitis (typically viral or dry-eye related corneal epithelial disease) cannot be drawn from an indication-similarity standpoint.
Mechanistically, the evidence pack’s own repurposing rationale for this candidate is cautionary rather than supportive: Lidocaine has no known reparative or anti-inflammatory action on corneal epithelium, and topical anaesthetics are known to delay corneal epithelial healing — the opposite of what treating this condition would require. The prediction should therefore be read as a knowledge-graph similarity signal only, not as a mechanistically grounded hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
South Africa Market Information
Lidocaine is currently not marketed in South Africa under this evidence pack (0 SAHPRA registrations recorded), so no product registration table is available.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: a blocking data gap exists — TFDA/SAHPRA-equivalent product-label warnings and contraindications have not yet been retrieved, which prevents a full initial safety assessment (S1) for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (punctate epithelial keratoconjunctivitis) has no supporting clinical trial or literature evidence (Evidence Level L5 — model prediction only), and the available mechanistic reasoning suggests topical anaesthetic use may delay rather than support corneal epithelial healing, working against the intended therapeutic direction.
To proceed, the following is needed:
- Product label warnings/contraindications (currently a Blocking data gap; needed for initial safety screening)
- Confirmed mechanism of action data linking Lidocaine to corneal/conjunctival pathology
- Independent preclinical or clinical evidence specifically evaluating Lidocaine’s effect on corneal epithelial healing before any further evaluation stage is considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.